A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

Alzheimer Disease Clinical Trial

— INTERCEPT-AD  

Official title:

A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04931459
• Other study ID #: ACU-001
• Secondary ID: 3U01AG053247
• Status: Completed
• Phase: Phase 1
• Start date: June 21, 2021
• Est. completion date: June 12, 2023

Study information

• Verified date: July 2023
• Source: Acumen Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: June 12, 2023
• Est. primary completion date: June 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Males or females ages 55 to 90 (inclusive).

2. Participant weighs at least 41 kg (90 lbs) and no more than 113 kg (250 lbs) before study drug administration.

3. Female participants must be surgically sterile or be at least two years post-menopausal or at least one year post-menopausal with an elevated follicle stimulating hormone (FSH). Male participants with a female partner of child-bearing potential must use adequate contraception.

4. Individual (or the participant's Legally Authorized Representative [LAR]) is able to give informed consent.

5. Are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

6. Must meet all of the following clinical criteria for MCI due to AD or mild AD at

Screening:

1. Participant meets NIA-Alzheimer's Association (NIA-AA) criteria for MCI due to AD or probable AD.

2. A global Clinical Dementia Rating (CDR) of 0.5 or 1.0.

3. A Mini-Mental State Examination (MMSE) score between 18 and 30 (inclusive).

4. A positive amyloid positron emission tomography (PET) scan.

7. Must consent to apolipoprotein E (APOE) genotyping.

8. If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least four weeks prior to Baseline and the participant must be willing to keep the doses stable throughout the duration of the study.

9. Must have a reliable informant or caregiver who is willing and able to perform all caregiver roles as specified in the caregiver Informed Consent Form (ICF).

Exclusion Criteria:

1. Receipt of any investigational biological drug within less than one year of Baseline or of any investigational small molecule drug within less than six months of Baseline. Receipt of any approved treatments that target amyloid plaques in the brain within less than one year of Baseline.

2. Currently receiving or likely to require the following types of anticoagulants:

coumarins and indandiones, Factor Xa inhibitors, heparins, thrombin inhibitors.

3. Has known humanized monoclonal antibody allergy or hypersensitivity.

4. History of significant neurological disease, other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson´s disease, or adult epilepsy.

5. Has had magnetic resonance imaging (MRI) or computerized tomography (CT) of brain within previous two years showing pathology that would be inconsistent with a diagnosis of AD.

6. Has MRI with results showing greater than four amyloid-related imaging abnormalities hemorrhage/hemosiderin deposition (ARIA-H), presence of any amyloid-related imaging abnormalities edema/effusions (ARIA-E), or superficial siderosis.

7. Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.

8. Current serious or unstable clinically important illness that, in the judgment of the Investigator, is likely to affect cognitive assessment including visual and hearing impairment, deteriorate, or affect the participant's safety or ability to complete the study, including psychiatric, hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrinological, immunologic, or hematologic disorders.

9. Has an ongoing or new clinically significant laboratory abnormality, as determined by the Investigator.

10. Has a history or presence of clinically significant abnormal 12-lead electrocardiogram (ECG) or an ECG with QT interval corrected using Fridericia's formula (QTcF) >470 msec for female participants or >450 msec for male participants. As the ECGs are obtained in triplicate and are meant to be interpreted together, if one of the three ECGs in the triplicate has a QTcF above the threshold, eligibility of the participant should be determined based on clinical judgment of the Investigator in consultation with the medical monitor. If two of the three ECGs in the triplicate have a QTcF above the threshold, then the participant would not be eligible.

11. Within one year before Screening, any of the following: myocardial infarction; moderate or severe congestive heart failure, New York Heart Association class III or IV; hospitalization for, or symptom of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known significant structural heart disease (eg, significant valvular disease, hypertrophic cardiomyopathy), or hospitalization for arrhythmia.

12. History of seizure, transient ischemic attack (TIA), or stroke within the last 18 months.

13. History of clinically significant carotid or vertebrobasilar stenosis or plaque.

14. History of a malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment within the last five years.

15. Current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the Investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study.

16. Are a suicide risk, as determined by meeting any of the following criteria:

1. Suicide attempt within the six months prior to Baseline.

2. Suicidal ideation as defined by a positive response to Question 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation section.

3. Significant risk of suicide, as judged by the site Investigator.

17. History of multiple concussions, significant head trauma, or objective change in neuropsychological function within the last five years.

18. History of human immunodeficiency virus (HIV).

19. History of alcohol or drug abuse/dependence within the last five years.

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• ACU193
Intravenous ACU193
• Placebo
Intravenous Placebo

Locations

Country	Name	City	State
United States	Abington Neurological Associates	Abington	Pennsylvania
United States	Orange County Research Institute	Anaheim	California
United States	Atlanta Center for Medical Research	Atlanta	Georgia
United States	Kerwin Medical Center	Dallas	Texas
United States	iResearch Atlanta	Decatur	Georgia
United States	Velocity Clinical Research	Hallandale Beach	Florida
United States	Clinical Trials Network	Houston	Texas
United States	Charter Research	Lady Lake	Florida
United States	AMC Research	Matthews	North Carolina
United States	Columbus Clinical Services	Miami	Florida
United States	Columbia University	New York	New York
United States	Hoag Hospital Newport Beach	Newport Beach	California
United States	Combined Research Orlando Phase I-IV	Orlando	Florida
United States	Progressive Medical Research	Port Orange	Florida
United States	Clinical Endpoints	Scottsdale	Arizona
United States	Santos Research Center	Tampa	Florida
United States	Advanced Memory Research Institute of NJ	Toms River	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
Acumen Pharmaceuticals	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and Nature of Treatment-Related Adverse Events (AE) or Serious Adverse Events (SAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)	Proportion of participants with AE, discontinuations due to AE or SAE, and withdrawals from the study due to AE	Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)
Primary	Change in Clinical Laboratory Tests	Incidence and clinically significant abnormal changes in clinical laboratory assessments (hematology, clinical chemistry, urinalysis)	Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)
Primary	Changes in 12-Lead ECGs	Clinically significant abnormal changes in 12-Lead ECGs for PR, QRS, QT, QTcF, and QTcB	Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)
Primary	Changes in the Columbia-Suicide Severity Rating Scale (C-SSRS)	Presence of suicidal ideation as defined by a positive response to Question 5 on the C-SSRS suicide ideation section	Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)
Primary	Changes in Magnetic Resonance Imaging (MRI)	Brain magnetic resonance imaging (MRI) findings to assess amyloid-related imaging abnormalities (ARIA), including incidence of ARIA-E (edema) or ARIA-H (hemosiderosis)	Baseline (predose) up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)
Secondary	Estimate Blood Levels of ACU193	Area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt)	Up to 140 days post dose
Secondary	Estimate Maximum Blood Levels of ACU193	Maximum observed blood concentration Cmax(obs).	Up to 140 days post dose.
Secondary	Estimate Time to Reach Maximum Blood Levels of ACU193	Time to reach Tmax(obs)	Up to 140 days post dose.
Secondary	Estimate Blood Levels of ACU193	Area under the plasma concentration-time curve from time 0 to infinity (AUC8)	Up to 140 days post dose.
Secondary	Estimate Clearance of ACU193	Clearance (CL)	Up to 140 days post dose
Secondary	Estimate Volume of Distribution of ACU193	Apparent volume of distribution at terminal phase (Vz)	Up to 140 days post dose